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Introduction
LEF, a DMARD, was launched in Japan in September 2003. An active metabolite of LEF, A771726, inhibits de novo pyrimidine synthesis [1, 2] . Its clinical effects appear rapidly and are comparable with those of MTX or SSZ [3, 4] . Initially, lung injury associated with LEF use was considered rare owing to its scant reports in Western countries where its use preceded that in Japan, although an increased risk of hospitalization for pneumonia associated with LEF has been reported recently [5] . However, soon after its launch in Japan, a number of patients who developed lung injury during LEF therapy was reported [6] [7] [8] [9] [10] , and some of them had a fatal outcome. A multivariate analysis of more than 5000 Japanese rheumatoid patients taking LEF to identify the risk factors showed that pre-existing interstitial pneumonia, use of a loading dose, cigarette smoking and a low body weight are significant risk factors for the development of LEF-induced lung injury [11] . In this study, we compared the background and clinical and laboratory features between patients who died of and those who recovered from LEF-induced lung injury, to elucidate the poor prognostic factors for the injury.
Methods

Patients and data analysed
For the launch of LEF, post-marketing surveillance (PMS) was required by the Japanese Ministry of Health, Labor, and Welfare to be carried out by Sanofi-Aventis Japan (formerly Aventis Pharma Japan), and to be supported by the Japan College of Rheumatology. All the patients who were administered with LEF were registered. Among these patients, those who were reported to have developed any lung injury during the therapy by the attending physicians until October 2006 were preliminarily enrolled in this study. The surveillance sheets and chest images of the enrolled patients who had sufficient data were evaluated by the members of the Study Committee for Leflunomide-Induced Lung Injury of the Japan College of Rheumatology. Inclusion criteria for LEF-induced lung injury were: (i) clearly, newly developed lung disease after LEF use; (ii) diffuse bilateral distribution; and (iii) that other causes including Pneumocystis pneumonia were excluded. The patients whose lung injury was presumed to be unrelated to LEF by either attending physicians or the committee were excluded from this study.
Among the included patients, those whose outcome of the injury was already known were examined for background features, LEF dose, A771726 level in serum, clinical features, laboratory data, treatment, outcome and histopathological findings from both the surveillance sheet and additional questionnaire answered by the attending physicians. Biopsy or autopsy specimens were re-examined by a committee member pathologist specialized in lung diseases, in reference to the reports primarily made by pathologists in the hospitals. The available chest roentgen images were reviewed by the members of the committee.
Statistical analyses
Clinical and laboratory data were compared between patients who died of and those who recovered from the injury, using unpaired t-test, Fisher's exact test or Mann-Whitney's U-test. The changes in the laboratory data from the start of LEF administration to lung injury onset were analysed using paired t-test. Statistical analysis was performed using a standard software package, Statview version 5.0 for Windows (Statview, Berkeley, CA, USA). P-values of <0.05 were considered statistically significant.
Results
Patients
Sixty-one of the 5784 patients registered in the PMS from September 2003 to June 2006 were reported as having a lung disease by their attending physicians. Surveillance sheets and chest images of 47 of these 61 patients were analysed. After examination by the committee members, 22 patients clearly met the criteria, and outcome information was available. Among them, 13 patients recovered from and 9 patients died of the injury.
Comparison of background and clinical features
The background and clinical features of the patients are listed in Table 1 . The mean age was higher in patients who died than in those without fatal outcome (P ¼ 0.11). Eight patients who died had a pre-existing interstitial lung disease, whereas less than half of the patients who recovered had one (P ¼ 0.07). Other patient profiles did not significantly differ between the groups. The loading and maintenance doses, the serum A771726 level at the injury onset and the number of days from the start of LEF administration to injury onset did not significantly differ either.
Hypoxaemia with an arterial blood oxygen level <60 Torr or oxygen saturation level <90% was observed in eight patients who died, and in four patients who recovered (P ¼ 0.01). Pulmonary function tests were not available. No significant differences were observed in the incidence of either fever, dyspnea, cough, sputum or rales. Ground glass opacities (GGOs) spread almost entirely from the upper to the lower lung fields in all the patients of both groups. Consolidation was observed in seven patients who died, and five patients who recovered (P ¼ 0.10). GGOs or consolidation appeared as a mosaic pattern on chest CT images. Follow-up images until the recovery were available in nine patients who recovered, in whom neither residual shadows of GGOs or consolidation nor structural distortion was noted.
LEF use was discontinued in all the patients, and no difference in colestyramine or steroid administration was found between the groups. One patient each in both groups underwent plasma exchange. Mechanical ventilation was required for seven patients who died, but not for the patients who recovered (P < 0.01).
Histopathological analysis was available for two patients who died and for one patient who recovered. The main finding in two autopsied cases was diffuse alveolar damage (DAD) showing both exudation and organization, including hyaline membrane formation [9] . Additionally, the usual interstitial pneumonia pattern with honeycomb formation in the lung periphery was observed in both patients. Transbronchial lung biopsy specimens from a patient who recovered showed alveolitis with lymphocyte infiltration into the interalveolar septa and Masson bodies in the intra-alveolar space.
Comparison of laboratory data
Laboratory data obtained during the course of lung injury are shown in Table 2 . The serum CRP level decreased after the start of LEF administration, and re-increased significantly at the lung injury onset in both groups. At the lung injury onset, the CRP level was significantly higher in patients who died than in patients who recovered. It remained high in patients who died, whereas it decreased in patients who recovered.
The peripheral blood lymphocyte count decreased before the lung injury onset to a level significantly lower than that at the start of LEF administration only in patients who died. The count decreased further at the injury onset to a level significantly lower than that at the start of LEF administration in both groups. The count at the injury onset did not differ between the groups. However, the count still remained low in patients who died, whereas it clearly returned to a level significantly higher than that at the injury onset, and almost the same as the preinjury level, in patients who recovered.
The serum albumin level decreased at the lung injury onset in both groups, but the level was lower in patients who died. The level decreased further only in patients who died, whereas it returned almost to the pre-injury level in patients who recovered. Thus, the level at death was lower than that at recovery.
The serum lactate dehydrogenase level and KL-6 level [12] at the injury onset were higher in patients who died than in patients who recovered, although the difference was not significant (793 AE 778 vs 393 AE 157 IU/ml and 1430 AE 803 vs 923 AE 535 pg/ml, respectively). 
Discussion
Immediately after the launch of LEF in Japan, a surprisingly high incidence of interstitial pneumonia and a high mortality ratio during its therapeutic course were observed. Since most cases of LEF-induced lung injury were reported from Japan, the genetic background should be elucidated in the future.
Analysis of PMS data in Japan revealed that the risk factors are pre-existing interstitial pneumonia, loading dose, smoking history and low body weight with odds ratios of 8.17, 3.97, 3.12 and 2.91, respectively [11] . In this study, we focused particularly on factors affecting the prognosis of LEF-induced lung injury.
All the patients except one who died of the injury had preexisting interstitial pneumonia. Although there was no statistically significant difference in the frequency of pre-existing interstitial pneumonia between groups who died and who recovered, it maybe because of the small patient population. Pre-existing interstitial pneumonia is also presumed to be a risk factor or a poor prognostic factor for MTX-or gefitinib-induced lung injury [13] [14] [15] [16] [17] [18] [19] . It would be better to avoid LEF administration to patients with pre-existing interstitial pneumonia [20] .
There were no differences in the loading and maintenance doses between the patient groups. That might be because almost all the patients were administered LEF just as indicated at the launch, before the studies on the elucidation of risks were carried out. Loading dose is determined as a risk factor for lung injury [11] .
The patients in both groups would have responded well to LEF, as was shown by a decrease in CRP level after its use. MTX-induced lung injury was also reported to develop after a good response [21] . Then, the CRP level showed a considerable re-increase at the injury onset, and it was much more severe in patients who died. Despite a supposedly good response, hypoalbuminaemia was still observed in patients who died during the treatment, and it became significantly more severe at the onset, indicating that hypoalbuminaemia, particularly that at the injury onset, is a poor prognostic factor. Hypoalbuminaemia was sustained in patients who died, in contrast to the return to the pre-injury level in patients who recovered.
A typical characteristic of the injury would be a decrease in the peripheral blood lymphocyte count. It decreased after the start of LEF administration, and clearly decreased further at the lung injury onset. In patients who died, the decrease was more evident and already observed during the therapy. After the injury onset, a further decrease was noted until the fatal outcome, whereas it returned to the pre-injury level upon recovery. Lymphocyte count decrease was also reported as a characteristic finding observed in MTX-induced lung injury [21] . Although the mechanism underlying lymphocyte depletion in peripheral blood in DMARD-induced lung injury remains to be elucidated, lymphocytopenia is possibly one of the most important laboratory markers and also an indicator of prognosis.
Chest CT images in this study showing diffuse GGOs forming mosaic patterns in the entire bilateral lungs were different from those of patient with rheumatoid lung disease. However, differentiating LEF-induced lung injury from Pneumocystis pneumonia only on the basis of radiological findings was difficult. Careful differentiation by examining the serum -D-glucan level and sputum is necessary. The pathological findings in autopsied lungs that showed irreversible organizing DAD were consistent with the clinical courses of patients who died being resistant to the treatment. Severe hypoxaemia and the necessity of mechanical ventilation indicate that such a serious lung injury induced by LEF might result in death.
In conclusion, pre-existing interstitial lung disease was frequently found to be associated with LEF-induced lung injury and would be a risk factor for poor prognosis. It would be better to examine the presence of pre-existing interstitial lung disease before the start of LEF administration, and to avoid LEF administration in patients with it. Decrease in peripheral blood lymphocyte count would be a typical characteristic of LEFinduced lung injury, and sustained lymphocytopenia would indicate poor prognosis. Clear hypoxaemia, necessity of mechanical ventilation, extremely elevated CRP level and hypoalbuminaemia indicate a very serious lung injury. The histopathological finding of patients who died of the injury was DAD.
Rheumatology key messages
Lung injury is a fatal complication of LEF-induced lung injury. Pre-existing interstitial pneumonia, high CRP, hypoalbuminaemia, hypoxaemia, lymphocytopenia and mechanical ventilation indicate the poor prognosis. Careful observation of poor prognostic factors is necessary to prevent death from LEF-induced lung injury.
